Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
Embracing Powertrain Diversity, GWM Continues to Enhance Clean Diesel Capabilities for Off-Roading
BAODING, China--(BUSINESS WIRE)--While new energy vehicles continue to gain momentum worldwide, efficient…
PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR
PROVISION Study, Prospective Randomized Trial Evaluating Clinical Outcomes of FFRangio Versus FFR…
ASICS EMEA reports growth in all channels and categories in Q1 2025
– ASICS EMEA today reported its Q1 2025 financial results, with revenues…
New LCA Study: XLERATOR hand dryers slash carbon footprint by 94% compared to paper towels
Latest Life Cycle Assessment (LCA) reveals Excel Dryer's high efficiency hand dryers…
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
- Full data from the Phase 3 TRuE-PN1 study, presented today in…
AppTech Payments Corp. Highlights Q4 2024 Financial and Strategic Developments
CARLSBAD, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (“AppTech…
The debate on MSCs is over; it’s time to promote MSC therapy in practice
TIANJIN, China, Feb. 26, 2025 /PRNewswire/ -- The debate on MSCs, mesenchymal…
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive…
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) Compared to Opdivo Monotherapy…
Patients experienced a 38% reduction in the risk of disease progression or…